Antiphospholipid Antibodies Affect Human Endometrial Angiogenesis: Protective Effect of a Synthetic Peptide (TIFI) Mimicking the Phospholipid Binding Site of β2glycoprotein I
Article first published online: 7 MAY 2013
© 2013 John Wiley & Sons Ltd
American Journal of Reproductive Immunology
Volume 70, Issue 4, pages 299–308, October 2013
How to Cite
Antiphospholipid antibodies affect human endometrial angiogenesis: protective effect of a synthetic peptide (TIFI) mimicking the phospholipid binding site of β2glycoprotein I. Am J Reprod Immunol 2013; 70: 299–308, , , , , , , , , .
- Issue published online: 13 SEP 2013
- Article first published online: 7 MAY 2013
- Manuscript Accepted: 1 APR 2013
- Manuscript Received: 13 FEB 2013
- MIUR GRANT. Grant Number: 2006061255
- Ricerca Corrente IRCCS Istituto Auxologico Italiano
- ISI (Istituto Scientifico Internazionale)
- Istituto Paolo VI
- Università Cattolica del Sacro Cuore
- Antiphospholipid antibodies;
- endometrial angiogenesis;
Aim of our study was to investigate whether TIFI, a syntetic peptide able to compete with anti-phospholipid antibodies (aPL) in the binding to endothelium, may restore aPL-inhibited endometrial angiogenesis.
The protective role of TIFI was evaluated on: i) aPL–inhibited of human endometrial endothelial cells (HEEC) angiogenesis in vitro; ii) aPL–inhibited vascular endothelial growth factor (VEGF) and metalloproteases (MMPs) expression; iii) aPL-inhibited Nuclear Factor-κB (NF-κB) and Extracellular signal–Regulated Kinase (ERK) activation and (iv) angiogenesis in vivo.
TIFI restores in a dose-dependent manner: i) aPL-mediated inhibition of HEEC angiogenesis in vitro and in vivo (P < 0.05), ii) VEGF (P < 0.001) and MMP–2 (P < 0.05) expression and iii) NF-κB DNA binding and ERK–1/2 activation (P < 0.05) inhibited by aPL.
Our results show for the first time the protective effects of TIFI, as represented by its ability to interfere with aPL mediated anti-angiogenic activity.